A Japanese team has found some existing medical agents effective in inhibiting RNA viruses, including the new coronavirus, through an experiment using induced pluripotent stem, or iPS, cells.
The results of the study were published in the online edition of European science journal FEBS Open Bio on Wednesday.
The medical agents include raloxifene, a drug for osteoporosis, remdesivir, an antiviral drug approved in Japan as a COVID-19 treatment, and pioglitazone, used to treat diabetes.
The team, including researchers from Kyoto University’s Center for iPS Cell Research and Application (CiRA), said that their findings would be useful in developing new treatments for viral diseases although clinical trials need to be conducted to finally confirm the effects of the drugs.
japantimes.co.jp/news/2021/...
FEBS Open Bio; Research Paper:
